The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

Bristol Myers Squibb surpassed analyst expectations with a strong Q2, as notable brands Eliquis, Opdivo, and Revlimid drove ...

Bristol Myers Squibb outperformed expectations in the second quarter, with boosted sales from key brands Eliquis, Opdivo, and ...

List today: Mission Produce, Inc. AVO: This fruits producer has seen the Zacks Consensus Estimate for its current year ...

BioNTech will expand its pipeline into antibody-drug conjugates (ADCs) and deepen its presence in oncology through an up-to-$1.67 billion collaboration with Duality Biologics (DualityBio).

Shares in BioNTech, which is also developing cancer treatments, were down 6.7% to hit a two-month low in Frankfurt. Its US-listed shares fell 5% in premarket trading, while Pfizer's shares fell 3.5%.

BioNTech and Pfizer had previously said they could make about 2 billion pandemic shots this year, enough to immunise 1 billion people. Next year, the partners could have capacity to make 3 billion ...